scholarly journals Treatment of Hepatitis B in Decompensated Liver Cirrhosis

2011 ◽  
Vol 2011 ◽  
pp. 1-11 ◽  
Author(s):  
Richard Guan ◽  
Hock Foong Lui
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Antiviral Agents ◽  
Antiviral Agent ◽  
Decompensated Cirrhosis ◽  
Decompensated Liver Cirrhosis ◽  
Chronic Hepatitis B Infection ◽  
Advanced Cirrhosis ◽  
Hepatitis B Treatment

Chronic hepatitis B infection progresses from an asymptomatic persistently infected state to chronic hepatitis, cirrhosis, decompensated liver disease, and/or hepatocellular carcinoma. About 3% of patients with chronic hepatitis develop cirrhosis yearly, and about 5% of individuals with hepatitis B cirrhosis become decompensated annually. The outcome for patients with decompensated cirrhosis is bleak. Lamivudine, the first oral antiviral agent available for hepatitis B treatment is safe and effective and can improve or stabilize liver disease in patients with advanced cirrhosis and viraemia. Viral resistance restricts its prolonged use. Entecavir and tenofovir are newer agents with excellent resistance profile to date. These and some other antiviral agents are being investigated for optimal use in this rather challenging patient group.

scholarly journals Management of chronic hepatitis B before and after liver transplantation

2017 ◽  
Vol 9 (1) ◽  
pp. 79-84 ◽  
Author(s):  
B Wang ◽  
K Agarwal ◽  
D Joshi
Keyword(s):  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Public Health Problem ◽  
Global Public Health ◽  
Chronic Hepatitis B Infection ◽  
Before And After ◽  
Related Liver Disease

Chronic hepatitis B infection is a global public health problem associated with significant morbidity and mortality. Persistent infection may evolve to liver cirrhosis and hepatocellular carcinoma, and hepatitis B-related liver disease is a common indication for liver transplantation. Patients with advanced liver disease should be treated with antiviral therapy which may result in clinical improvement. The management of patients after liver transplant then focuses on preventing hepatitis B recurrence in the graft. With the introduction of prophylactic treatment, patient and graft survival has improved significantly. In this review, we will discuss the management of patients with hepatitis B-related cirrhosis, both compensated and decompensated. We also review the management of hepatitis B after liver transplantation.

scholarly journals “Black box warning” rash with entecavir - case report

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Xiong Khee Cheong ◽  
Zhiqin Wong ◽  
Norazirah Md Nor ◽  
Bang Rom Lee
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agent ◽  
Skin Condition ◽  
Hepatitis B Infection ◽  
Genetic Barrier ◽  
Chronic Hepatitis B Infection ◽  
First Case ◽  
Oral Corticosteroids

Abstract Background Hepatitis B infection is a significant worldwide health issue, predispose to the development of liver cirrhosis and hepatocellular carcinoma. Entecavir is a potent oral antiviral agent of high genetic barrier for the treatment of chronic hepatitis B infection. Cutaneous adverse reaction associated with entecavir has rarely been reported in literature. As our knowledge, this case was the first case reported on entecavir induced lichenoid drug eruption. Case presentation 55 year old gentlemen presented with generalised pruritic erythematous rash on trunk and extremities. Six weeks prior to his consultation, antiviral agent entecavir was commenced for his chronic hepatitis B infection. Skin biopsy revealed acanthosis and focal lymphocytes with moderate perivascular lymphocyte infiltration. Skin condition recovered completely after caesation of offending drug and short course of oral corticosteroids. Conclusion This case highlight the awareness of clinicians on the spectrum of cutaneous drug reaction related to entecavir therapy.

Sign in / Sign up

Export Citation Format

Share Document